Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Hospital | 163.2 | 154.6 | 144.3 | | | | | |
| Private Office | 77.2 | 75.8 | 75.6 | | | | | |
| Corporate & Other | 2.9 | 3.1 | 2.4 | | | | | |
| Wound & Surgical | 264.9 | 238.9 | 213.5 | | | | | |
| Total revenues [+] | 267.8 | 258.6 | 248.2 | 299.3 | 359.1 | 321.1 | 221.7 | 187.3 |
| Products | 267.8 | 258.6 | 248.2 | 299.3 | 359.1 | 321.1 | 221.7 | 187.3 |
| Revenue growth [+] | 3.6% | 4.2% | -17.0% | -16.7% | 11.8% | 44.8% | 18.4% | 58.4% |
| Hospital | 5.6% | 7.1% | | | | | | |
| Private Office | 1.8% | 0.2% | | | | | | |
| Corporate & Other | -4.7% | 29.2% | | | | | | |
| Wound & Surgical | 10.9% | 11.9% | | | | | | |
| Regenerative Medicine | | -48.7% | | | | | | |
| Cost of goods sold | 48.3 | 43.3 | 39.3 | 43.1 | 36.4 | 35.2 | 30.9 | 20.2 |
| Gross profit | 219.5 | 215.3 | 208.9 | 256.2 | 322.7 | 285.9 | 190.8 | 167.1 |
| Gross margin | 82.0% | 83.3% | 84.2% | 85.6% | 89.9% | 89.0% | 86.0% | 89.2% |
| Selling, general and administrative | 208.8 | 198.4 | 181.0 | 198.2 | 258.5 | 220.1 | 173.4 | 133.4 |
| Research and development | 22.8 | 17.3 | 11.7 | 11.1 | 15.8 | 17.9 | 14.3 | 8.4 |
| Other operating expenses | 12.2 | 3.8 | 59.5 | 66.5 | 51.3 | | | 0.9 |
| EBITDA [+] | -20.9 | 0.2 | -37.5 | -13.1 | 3.0 | 52.0 | 6.4 | 27.1 |
| EBITDA growth | -10510.4% | -100.5% | 185.7% | -538.8% | -94.2% | 718.2% | -76.6% | 193.7% |
| EBITDA margin | -7.8% | 0.1% | -15.1% | -4.4% | 0.8% | 16.2% | 2.9% | 14.5% |
| Depreciation | 3.3 | 4.4 | 5.8 | 6.5 | 5.9 | 4.1 | 3.3 | 1.8 |
| EBITA | -24.3 | -4.2 | -43.3 | -19.7 | -2.9 | 47.9 | 3.0 | 25.3 |
| EBITA margin | -9.1% | -1.6% | -17.4% | -6.6% | -0.8% | 14.9% | 1.4% | 13.5% |
| Amortization of intangibles | 0.7 | 0.8 | 1.1 | 1.0 | 1.0 | 1.7 | 2.1 | 0.9 |
| EBIT [+] | -25.0 | -5.0 | -44.4 | -20.7 | -3.9 | 46.2 | 0.9 | 24.4 |
| EBIT growth | 401.2% | -88.8% | 114.2% | 427.9% | -108.5% | 5128.8% | -96.4% | 243.2% |
| EBIT margin | -9.3% | -1.9% | -17.9% | -6.9% | -1.1% | 14.4% | 0.4% | 13.0% |
| Non-recurring items [+] | | 0.1 | 1.0 | 0.4 | | | | |
| Asset impairment | | 0.1 | 1.0 | 0.4 | | | | |
| Interest expense | 5.0 | 5.0 | 7.9 | 4.7 | 0.2 | 0.1 | | 0.1 |
| Interest expense | 5.0 | 5.0 | 7.9 | 4.7 | 0.2 | 0.1 | | 0.1 |
| Other income (expense), net [+] | 0.0 | 0.0 | -8.2 | 0.3 | 0.7 | -1.0 | -0.3 | |
| Gain (loss) on sale of business | | | | | | -1.0 | | |
| Gain (loss) on debt retirement | | | -8.2 | | | | | |
| Other | 0.0 | 0.0 | 0.0 | 0.3 | | | -0.3 | |
| Pre-tax income | -30.0 | -10.0 | -61.5 | -25.6 | -3.4 | 45.1 | 0.5 | 24.3 |
| Income taxes | 0.2 | 0.2 | -12.3 | 0.0 | 26.6 | -19.6 | 0.2 | -5.2 |
| Tax rate | | | 19.9% | 0.0% | | | 28.4% | |
| Net income | -36.8 | -16.4 | -83.3 | -25.6 | -30.0 | 64.7 | 0.4 | 29.4 |
| Net margin | -13.7% | -6.3% | -33.6% | -8.5% | -8.3% | 20.2% | 0.2% | 15.7% |
| |
| Basic EPS [+] | ($0.33) | ($0.15) | ($0.77) | ($0.24) | ($0.28) | $0.61 | $0.00 | $0.28 |
| Growth | 118.9% | -80.7% | 221.8% | -15.8% | -146.5% | 16466.4% | -98.7% | 372.8% |
| Diluted EPS [+] | ($0.33) | ($0.15) | ($0.77) | ($0.24) | ($0.28) | $0.56 | $0.00 | $0.26 |
| Growth | 118.9% | -80.7% | 221.8% | -15.8% | -150.9% | 16001.0% | -98.7% | 372.0% |
| |
| Shares outstanding (basic) [+] | 112.9 | 110.4 | 108.3 | 106.9 | 105.6 | 106.1 | 105.9 | 105.9 |
| Growth | 2.3% | 1.9% | 1.2% | 1.3% | -0.5% | 0.2% | 0.0% | 0.1% |
| Shares outstanding (diluted) [+] | 112.9 | 110.4 | 108.3 | 106.9 | 105.6 | 116.1 | 112.6 | 113.6 |
| Growth | 2.3% | 1.9% | 1.2% | 1.3% | -9.1% | 3.1% | -0.9% | 0.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|